Team MSB,
With this regulatory leeway in Japan, the 2nd largest developed Healthcare market, I'm really puzzled as to why MSB yet commercialised CHF and CLBP there given positive p2 & p3 results. We are further known in market through JCR and Temcell 40% share of GVHD market. Gigantic opportunity. Would really value your astute perspective! Thankyou.
Team MSB, With this regulatory leeway in Japan, the 2nd largest...
-
- There are more pages in this discussion • 2,987 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.5¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.101B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | 99.5¢ | 96.0¢ | $2.283M | 2.340M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29300 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |